Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Semin Arthritis Rheum. 2019 Nov 15;50(3):546–552. doi: 10.1016/j.semarthrit.2019.11.004

Table 5:

Treatment outcomes for 20 cardiac sarcoidosis patients treated with a TNF-α inhibitor

TNF- αInhibitor Indication/Outcome Full Cohort (n= 20) Definite CS (n=3) Probable CS (n=10) Possible CS (n=7)
Reason for initiating TNF-α inhibitor
 Worsening heart failure 3 1 2 0
 Worsening arrhythmia 9 2 3 4
 Worsening disease activity on FDG-PET 17 2 9 6
  Improvement in FDG-PET after TNF- α inhibitor initiation 17 2 9 6
Time from diagnosis to TNF- α inhibitor initiation (mean), months 16 21 15 15
Prednisone dose 6 months before TNF- α inhibitor initiation (mean), mg 23 20 27 22
Prednisone dose 6 months after TNF- α inhibitor initiation (mean), mg 4 0 4 6
Time to stop prednisone after TNF- α inhibitor initiation (mean), months 9 8 11 8
LVEF within 12 months before TNF- α inhibitor initiation (mean), % 41 39 47 44
LVEF within 12 months after TNF- α inhibitor initiation (mean), % 44 41 49 46
*

Data are number (%). CS = cardiac sarcoidosis; TNF-α = tumor necrosis factor alpha; LVEF = left ventricular ejection fraction.